entertainment -WSS

entertainment

author：focus 2025-09-28 00:51:41 - browse：82624

Jennifer Doudna Feng Zhang CRISPR — CRISPR pioneers Jennifer Doudna and Feng Zhang Illustration: STAT; Photos: AP, Getty

The revolution started in silence.

Jennifer Doudna and Emmanuelle Charpentier, now Nobelists, published their first paper announcing a new enzyme for editing DNA in Science in June 2012. It was called CRISPR-Cas9. It wasn’t until January 2013 that the first paper showing the enzyme would work in cells, from Feng Zhang, was published, also in Science. A similar paper from George Church came out at the same time.

No major media outlet covered the papers. The first story on CRISPR was published that March. But within the ivory tower of academia, it was clear something big was building, as requests for the technology poured in from other researchers and Zhang set up an assembly line in his laboratory to distribute it, with students carrying carefully packed samples to a FedEx office down the street.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： My daughter's legacy lives on through her writing, phage therapy

focus

WSS

The system is set up to fail children with medical complexity

Cassava reveals details — and problems — with Alzheimer's study

The FDA weighs the risks of candy

Deposition: Sackler embraced plan to conceal OxyContin’s strength

CDC recommends rationing of RSV shot due to shortages

Statins may not be needed by millions of people, study suggests

entertainment

entertainment

focus

Dobbs anniversary: the lost opportunity of abortion as health care

Chimpanzees, like humans and whales, get menopause: Study

Duchenne breakthrough therapy leaves behind pioneering families

Biden's order seeks to regulate AI risk without stifling innovation

Walensky prepares to leave CDC — and Congress — behind

CDC recommends rationing of RSV shot due to shortages

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

NIH tests clinical research in primary care with $30 million program

focus

Cassava reveals details — and problems — with Alzheimer's study

Meta's Zuckerberg and Chan on track to put $50 billion into science

Testing for cancer recurrence creates a new limbo for patients

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Lilly's Alzheimer's drug donanemab backed by FDA advisers

How faith leaders like me can help address America's obesity epidemic

Wikipedia

explore

focus

hotspot